111 results
DEFA14A
IBRX
ImmunityBio Inc
29 Apr 22
Additional proxy soliciting materials
12:00am
on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important … in the shaded box above available
when you access the website and follow the instructions.
If you want to receive a paper or e-mail copy of the proxy
8-K
EX-99.1
IBRX
ImmunityBio Inc
23 Apr 24
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class
6:17am
.
Patient Assistance Program
ImmunityBio is committed to helping patients access ANKTIVA and will be offering services to overcome access barriers … . ImmunityBio’s Patient Assistance Program will be operational in mid-May. This program is designed to help those in need, ensuring access to ImmunityBio’s
8-K
EX-10.1
IBRX
ImmunityBio Inc
12 Jan 22
Entry into a Material Definitive Agreement
8:35am
and Warranties
Indemnification by Seller
Indemnification by Buyer
Indemnification Procedures
Other Indemnification Provisions
Insurance
Cooperation, Access … provided adequate access to the personnel, properties, premises, and other documents and data of Seller for such purpose. Buyer acknowledges and agrees
8-K
EX-99.1
lcu 5o3x7pd8u
12 Jan 22
Entry into a Material Definitive Agreement
8:35am
10-K
EX-10.23
g561zgpbs36zoyiapbv
30 Mar 16
Annual report
12:00am
S-4
EX-10.12
1mf9n zuniu7kqaspw
19 Jan 21
Registration of securities issued in business combination transactions
5:20pm
8-K
EX-99.3
se0i3vbev 0rl4b3bm3
9 Mar 21
ImmunityBio and NantKwest Complete Merger
9:58pm
8-K
EX-99.1
1ul4ucix
24 Jun 20
Other Events
5:26pm
S-4
EX-10.23
vh3ivgp
19 Jan 21
Registration of securities issued in business combination transactions
5:20pm